At Rush University Medical Center, we are putting your safety first. For information about COVID-19, see the latest updates. Rush accepts donations to support our response effort, staff, and patients and families.

Excellence is just the beginning.
Services & Conditions

Conditions and Treatments

View Alphabetically

Find a Doctor
Advanced Doctor Search >

Octavio Vega, MDAt the end of the visit, my goal is to have the patients feel more informed and to feel like their issues have been properly addressed.

— Octavio Vega, MD, internist

Patricia Graham, MDI enjoy the challenges of piecing together the puzzle – putting difficult, complicated signs and symptoms together and trying to formulate a diagnosis.

— Patricia Graham, MD, internist

Hear more from doctors at Rush.

Patients & Visitors

Patients

Directions and Parking

Locations
Health & Wellness

Health News and Advice to Fit Your Life

The choices you make each day can have a huge effect on your health. Rush offers a wealth of resources to help you make good ones.

5 Things You Can Do to Prevent CancerMan riding bike on beachHow you can devise a cancer prevention action plan.

Combating Social Media DysmorphiaWoman washing carrots in sinkHow to love yourself — and your selfies — without filters or fillers.

 

About Us

Translate

French German Italian Portuguese Russian

Study for Patients with Completely Resected Stage IB to Stage IIIA Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer

Clinical Trial Title: 
A phase III, open-label, randomized study to evaluate the efficacy and safety of adjuvant alectinib versus adjuvant platinum-based chemotherapy in patients with completely resected stage IB to stage IIIA anaplastic lymphoma kinase-positive NSCLC.
Clinical Trial Protocol ID: 
18020105
Clinical Trial Investigator Name: 
Mary Jo Fidler, MD
Clinical Trial Protocol Description: 

This randomized, active-controlled, multi-center, open-label, phase III study is designed to compare the effects, good or bad, of alectinib versus platinum-based chemotherapy for patients with a specific type of lung cancer. Participants in the experimental arm will receive alectinib at 600 mg orally twice daily for 24 months. Participants in the control arm will receive a platinum based chemotherapy regimen for 4 cycles. Following treatment completion, participants will be followed until disease recurrence.

Clinical Trial Eligibility Criteria: 

In order to participate you must meet the following criteria:

  • Are at least 18 yearsof age.
  • Have complete resection of histologically confirmed stage IB (tumor ≥ 4 cm) to stage IIIA (T2-3 N0, T1-3 N1, T1-3 N2, T4 N0-1) non-small cell lung cancer.
  • Have documented ALK-positive disease.

You will be excluded from the study if any of the following criteria apply to you:

  • Have had prior adjuvant radiotherapy or exposure to systemic chemotherapy and ALK inhibitors.
  • Are a stage IIIA N2 patient that, in the investigator's opinion, should receive post-operative radiotherapy treatment.

This is a partial list of inclusion and exclusion criteria.

Clinical Trial Area: 
Lung and Chest Tumors
Contact Email: 
cancer_studies@rush.edu
Contact Phone: 
(312) CANCER-1
Contact Name: 
Rush Cancer Center Clinical Trials Office